Vaccines
Antengene's ATG-201 Autoimmune Therapy Receives Australian Clinical Trial Approval
Biotech company Antengene has secured regulatory clearance in Australia to begin Phase I trials of ATG-201, a bispecific antibody targeting B cell-related autoimmune diseases, marking the therapy's expansion beyond China into international markets....